SCHEMBL2850002

SCHEMBL2850002

NC(=O)Nc1cccc(C(N)=O)c1

nearest known ligand 0.67

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
PARP1 P09874 16/20 0.63
PARP10 Q53GL7 12/20 0.63
PARP15 Q460N3 7/20 0.63
PARP14 Q460N5 4/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5425792 0.86 MEN1 (0.65) MEN1KMT2APARP1PARP10PARP15
SCHEMBL5210059 0.86 KMT2A (0.62) MEN1KMT2A
SCHEMBL4795890 0.86 KMT2A (0.66) MEN1KMT2A
SCHEMBL28280295 0.86 MEN1 (0.65) MEN1KMT2APARP1PARP10PARP15
SCHEMBL4893340 0.86 PARP1 (0.66) MEN1KMT2APARP1PARP10PARP15
SCHEMBL3690365 0.85 MAPT (0.59) MEN1KMT2A
SCHEMBL408480 0.85 PARP1 (0.63) MEN1KMT2APARP1PARP10PARP15
SCHEMBL895690 0.85 MEN1 (0.63) MEN1KMT2APARP1PARP10PARP15
Urea SCHEMBL307661 0.85 KMT2A (0.60) MEN1KMT2A
SCHEMBL4531507 0.85 ALDH1A1 (0.71) MEN1KMT2APARP1PARP10PARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
US-20190196073-A1 COMPOSITION, FILM, NEAR INFRARED CUT FILTER, PATTERN FORMING METHOD, LAMINATE, SOLID IMAGE PICKUP ELEMENT, IMAGE DISPLAY DEVICE, CAMERA MODULE, AND INFRARED SENSOR FUJIFILM CORPORATION (JP) 2019-06-27 US disclosed
WO-2017030859-A1 CCK2R-DRUG CONJUGATES ENDOCYTE, INC. (US) 2017-02-23 WO disclosed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed
CN-1051079-C Benzodiazepine * derivatives, process for their preparation and pharmaceutical compositions containing them YAMANOUCHI PHARMA CO LTD (JP) 2000-04-05 CN disclosed
US-5719151-A PHTHALAZINEDIONE COMPOUND; POLYMERASE INHIBITOR SHALL SYDNEY (GB) 1998-02-17 US disclosed
CN-1075717-A Benzodiazepine * derivatives YAMANOUCHI PHARMA CO LTD (JP) 1993-09-01 CN disclosed
US-5017211-A Herbicides CIBA-GEIGY CORPORATION (US) 1991-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 MEN1 4543/4885KMT2A 2659/4885PARP1 3600/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 MEN1 4543/4885KMT2A 2659/4885PARP1 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.